[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 7, Number 1 (2-2017) ::
Iran J Ped Hematol Oncol 2017, 7(1): 48-56 Back to browse issues page
Methylenetetrahydrofolate Reductase Polymorphisms in Iranian Patients with Glanzmann’s Thrombasthenia
Shima Kazemzadeh, Rezvan Mohammadi, Fatemeh Shadkam Farokhi, Alireza Shafiian, Mohammad Faranoush, Alireza Farsinejad , Fereydoun Ala
MD Pathology and Stem Cell Research Center, Kerman University of Medical Sciences, Kerman, Iran
Abstract:   (594 Views)

Background: The most common polymorphisms identified in the Methylenetetrahydrofolate reductase (MTHFR) gene, C677T and A1298C lead to defective activity of this enzyme and increase the risk of venous and arterial thrombosis. There are limited investigations regarding the effects of thrombogenic polymorphisms on the clinical phenotypes of rare hereditary hemorrhagic disorders like Glanzmann's thrombasthenia (GT) and
the exact correlation between MTHFR polymorphisms and GT is not well established. This calls for further studies in populations with a large number of such patients. So, this study was performed to question whether coinheritance of MTHFR polymorphisms and GT can modulate the clinical phenotype of GT.
Material and Methods: In the present case-control study which performed at Pathology and Stem Cell Research Center at Kerman University of Medical Sciences, 65 patients with GT and 100 normal voluntary blood donors as the control group were evaluated. The mean (SD) age of patients and the control group were 2.33±1.54 years (range 0-5 years) and 2.6±1.72, respectively. The detection of MTHFR C677T and A1298C polymorphisms was carried out using a Polymerase Chain Reaction- Restriction Fragment Length Polymorphism (PCR-RFLP) method. In accord with the Glanzmann's Thrombasthenia Italian Team (GLATIT) Protocol, the clinical severity of bleeding in patients with GT was determined. Two tests of descriptive statistics (i.e. frequencies) and Chi-square, using the SPSS version 19, were employed to analyze the data.
Results: Based on results, there were no significant statistical differences in the prevalence of the MTHFR C677T polymorphism (P=0.703) or the MTHFR A1298C polymorphism (P=0.187) between patients and the control group. In addition, no association between the severity of bleeding and these polymorphisms was found (P=0.385).
Conclusions: It was concluded that the thrombogenic mutations of MTHFR do not solely modulate the severity of clinical symptoms in patients with GT.

Keywords: Glanzmann's thrombasthenia, Polymorphism, Methylenetetetrahydrofolate reductase, Rare hereditary bleeding disorders
Full-Text [PDF 276 kb]   (194 Downloads)    
Type of Study: Research | Subject: Special
Received: 2016/12/18 | Accepted: 2016/12/18 | Published: 2016/12/18
Add your comments about this article
Your username or email:

Write the security code in the box >



XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Kazemzadeh S, Mohammadi R, Shadkam Farokhi F, Shafiian A, Faranoush M, Farsinejad A et al . Methylenetetrahydrofolate Reductase Polymorphisms in Iranian Patients with Glanzmann’s Thrombasthenia. Iran J Ped Hematol Oncol. 2017; 7 (1) :48-56
URL: http://ijpho.ssu.ac.ir/article-1-286-en.html
Volume 7, Number 1 (2-2017) Back to browse issues page
Iranian Journal of Pediatric Hematology and Oncology
Persian site map - English site map - Created in 0.21 seconds with 836 queries by yektaweb 3460